- Home
- BRT vs AMRN Comparison
BRT vs AMRN Comparison
Compare BRT & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$14.88
HOLD
Current Price
$15.04
Company Overview
Basic Information| Metric | BRT | AMRN |
|---|---|---|
| Founded | 1972 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.9M | 339.8M |
| IPO Year | N/A | 1993 |
Fundamental Metrics
Financial Performance| Metric | BRT | AMRN |
|---|---|---|
| Price | $14.88 | $15.04 |
| Analyst Decision | Strong Buy | Strong Sell |
| Analyst Count | 2 | 1 |
| Target Price | ★ $19.75 | $12.00 |
| AVG Volume (30 Days) | 56.0K | ★ 98.7K |
| Earning Date | 11-06-2025 | 10-29-2025 |
| Dividend Yield | ★ 6.80% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $98,001,000.00 | ★ $226,733,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.72 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.30 | N/A |
| 52 Week Low | $14.00 | $7.08 |
| 52 Week High | $19.01 | $20.90 |
Technical Indicators
Market Signals| Indicator | BRT | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 57.59 | 52.89 |
| Support Level | $14.54 | $14.86 |
| Resistance Level | $14.89 | $16.80 |
| Average True Range (ATR) | 0.26 | 0.77 |
| MACD | 0.03 | 0.26 |
| Stochastic Oscillator | 100.00 | 52.99 |
Price Performance
Historical Comparison BRT
AMRN
About BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.